Patents by Inventor Sharron Ladd

Sharron Ladd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate
    Patent number: 11932701
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: March 19, 2024
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1
    Publication number: 20220169745
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 2, 2022
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY
    Publication number: 20220143208
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: August 31, 2021
    Publication date: May 12, 2022
    Applicant: ImmunoGen, Inc.
    Inventors: Christina N. CARRIGAN, Kathleen R. WHITEMAN, Gillian PAYNE, Sharron LADD
  • Method for identifying an ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibody
    Patent number: 11198736
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: December 14, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Juliantro Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Methods for increasing efficacy of FOLR1 cancer therapy
    Patent number: 11135305
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 5, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1
    Publication number: 20200325240
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 15, 2020
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Methods of using antibodies to detect folate receptor 1 (FOLR1)
    Patent number: 10544230
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 28, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1
    Publication number: 20190023805
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: June 7, 2018
    Publication date: January 24, 2019
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Methods for Increasing Efficacy of FOLR1 Cancer Therapy
    Publication number: 20180200383
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: November 9, 2017
    Publication date: July 19, 2018
    Applicant: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodies
    Patent number: 10017578
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 10, 2018
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1
    Publication number: 20170306041
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 26, 2017
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Monoclonal antibodies for detection of folate receptor 1
    Patent number: 9637547
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: May 2, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Antibodies and Assays for Detection of Folate Receptor 1
    Publication number: 20150093388
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 2, 2015
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Methods for Increasing Efficacy of FOLR1 Cancer Therapy
    Publication number: 20140363453
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: April 4, 2014
    Publication date: December 11, 2014
    Applicant: ImmunoGen, Inc.
    Inventors: Christina N. CARRIGAN, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • Methods for increasing efficacy of FOLR1 cancer therapy
    Patent number: 8709432
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 29, 2014
    Assignee: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • Methods for Increasing Efficacy of FOLR1 Cancer Therapy
    Publication number: 20120282175
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: November 8, 2012
    Applicant: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd